Clinical Trials Logo

Clinical Trial Summary

To evaluate the efficacy, safety and tolerability of multiple doses of QBW251 vs placebo administered orally, on airway function, lung volume, and quality of life in patients with chronic obstructive pulmonary disease (COPD)


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02449018
Study type Interventional
Source Novartis
Contact
Status Completed
Phase Phase 2
Start date April 30, 2015
Completion date January 23, 2017

See also
  Status Clinical Trial Phase
Completed NCT00108823 - The HERO-study: Effects of Roflumilast in Patients With COPD (Chronic Obstructive Pulmonary Disease) (BY217/M2-121) Phase 3
Completed NCT03064113 - Effects of TD-4208 on FEV1 in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Phase 2
Completed NCT00496470 - Evaluation of Efficacy and Safety of Symbicort® as an add-on Treatment to Spiriva® in Patients With Severe COPD. Phase 4
Completed NCT02442206 - Effect of QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) on Cardiac Function in COPD Patients Phase 4
Completed NCT03095456 - Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD Phase 3
Completed NCT02615795 - Tele Health Monitoring Service for Patients With Chronic Obstructive Pulmonary Disease N/A